I. Blancas
26 Papers
6 Citations
I. Blancas is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Juan Miguel Cejalvo,Eduardo Martínez de Dueñas,Patricia Galván,Susana García-Recio,Octavio Burgués Gasión,Laia Paré,Silvia Antolín,Rossella Martinello,I. Blancas,Barbara Adamo,Angel Guerrero-Zotano,Montserrat Muñoz,Paolo Nuciforo,Maria Vidal,Ramon Perez,Jose Ignacio Chacon Lopez-Muniz,Rosalia Caballero,Vicente Peg,Eva Carrasco,Federico Rojo,Charles M. Perou,Javier Cortes,Vincenzo Adamo,Joan Albanell,Roger R. Gomis,Ana Lluch,Aleix Prat +26 more
TL;DR: Comparing intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients revealed the value of stratifying gene expression by both cancer subtype and tissue type, providing clinicians more refined tools to evaluate prognosis and treatment.
Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.
Hope S. Rugo,Joyce O'Shaughnessy,Frances M. Boyle,Masakazu Toi,Reuben James Broom,I. Blancas,Mahmut Gumus,Tetsumasa Yamashita,Y. H. Im,PS Rastogi,Flora Zagouri,C. Song,M. Campone,Belen San Antonio,Ashwin Shahir,Maarten Hulstijn,S. Zimmermann,Ran Wei,S. Johnson,Mattea Reinisch,Sara M. Tolaney +20 more
TL;DR: Abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone as discussed by the authors .
72
Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
Mercedes Zafra-Ceres,Tomás de Haro,Esther Farez-Vidal,I. Blancas,Fernando Bandres,Eduardo Martinez de Dueñas,Enrique Ochoa-Aranda,Jose Antonio Gómez-Capilla,Carolina Gomez-Llorente +8 more
TL;DR: CYP2D6*4/*4 genotype was inversely associated with 4-hydroxy tamoxifen and endoxifens levels, and CYP2C19 genotyping appears advisable before the prescription of tamoxIFen therapy.
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion
Ana Lluch,Ana M. Gonzalez-Angulo,David Casadevall,Agda Karina Eterovic,Eduardo Martínez de Dueñas,Xiaofeng Zheng,Angel Guerrero-Zotano,Shuying Liu,Ramon Perez,Ken Chen,Jose Ignacio Chacon,Gordon B. Mills,Silvia Antolín,I. Blancas,Paula López-Serra,Eva Carrasco,Rosalia Caballero,Aleix Prat,Federico Rojo,Abel Gonzalez-Perez,Funda Meric-Bernstam,Joan Albanell +21 more
TL;DR: In this paper, the association between genomic remodeling and subtype conversion in paired primary and metastatic BC samples was analyzed, showing that mutations in metastases showed a higher estimated cancer cell fraction (CCF) than in primary tumours.
22
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Sara A. Hurvitz,Aditya Bardia,Vanesa Quiroga,Yeon Hee Park,I. Blancas,José Luis Alonso-Romero,A. Vasiliev,Hryhoriy Adamchuk,M. Ramos Terjo Salgado,Denise A. Yardley,O. Berzoy,P. Zamora-Auñón,David W. Chang,Gonzalo Spera,Cloris Xue,Erika Chaul Ferreira,Tanja Badovinac Crnjevic,Pablo Perez-Moreno,Vanesa Lopez-Valverde,Jutta Steinseifer,Tharu M. Fernando,Heather M. Moore,Peter A. Fasching +22 more
TL;DR: The primary and final analyses of the coopERA Breast Cancer study report whether giredestrant, a highly potent, non-steroidal, oral SERD, would show a stronger anti-proliferative effect than anastrozole after 2 weeks for oestrogen receptor-positive, HER2-negative, untreated early breast cancer.
16